07:53 AM EDT, 06/24/2025 (MT Newswires) -- Nuvation Bio ( NUVB ) said Tuesday that taletrectinib has been added as a preferred agent in the updated National Comprehensive Cancer Network clinical practice guidelines for non-small cell lung cancer, or NSCLC.

The guidance now supports taletrectinib as a treatment option for both first-line and subsequent therapy in ROS1-positive NSCLC, including for patients with brain metastases or resistance mutations, the company said.

Nuvation Bio ( NUVB ) also said the update follows the June 11 US Food and Drug Administration's approval of the drug for advanced or metastatic ROS1+ NSCLC in adults.

Shares of the company rose more than 6% in recent premarket activity Tuesday.

Price: 2.16, Change: +0.13, Percent Change: +6.40